Cargando…

Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status

PURPOSE: The Ki-67/MIB-1 labeling index (LI) is clinically used to differentiate between high and low-grade gliomas, while its prognostic value remains questionable. Glioblastoma (GBM) expressing wild-type isocitrate dehydrogenase IDH(wt), a relatively common malignant brain tumor in adults, is char...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tini, Paolo, Yavoroska, Mariya, Mazzei, Maria Antonietta, Miracco, Clelia, Pirtoli, Luigi, Tomaciello, Miriam, Marampon, Francesco, Minniti, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322955/ https://www.ncbi.nlm.nih.gov/pubmed/37227648 http://dx.doi.org/10.1007/s11060-023-04342-2

Ejemplares similares

The prognostic role of Ki-67/MIB-1 in meningioma: A systematic review with meta-analysis
por: Liu, Ning, et al.
Publicado: (2020)

Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy
por: Tini, Paolo, et al.
Publicado: (2017)

The Prognostic Role of Ki-67/MIB-1 in Cervical Cancer: A Systematic Review with Meta-Analysis
por: Pan, Denghua, et al.
Publicado: (2015)

IMMUNOHISTOCHEMICAL ANALYSIS BY KI67 AND IDH1 IN PATIENTS WITH CHONDROSARCOMA
por: RIBEIRO, MARCELO BARBOSA, et al.
Publicado: (2023)

Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer.
por: Dettmar, P., et al.
Publicado: (1997)

Estrogen Receptor-Negative Breast Ductal Carcinoma: Clinicopathological Features and Mib-1 (Ki-67) Proliferative Index Association
por: MdPaiman, Noorasmaliza, et al.
Publicado: (2014)

Clinical and Prognostic Implications of 1p/19q, IDH, BRAF, MGMT Promoter, and TERT Promoter Alterations, and Expression of Ki-67 and p53 in Human Gliomas
por: Yang, Zixi, et al.
Publicado: (2021)

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
por: Yang, Pei, et al.
Publicado: (2015)

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
por: Radke, Josefine, et al.
Publicado: (2019)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
por: Marchi, Francesco, et al.
Publicado: (2020)

The diagnostic and prognostic values of Ki-67/MIB-1 expression in thyroid cancer: a meta-analysis with 6,051 cases
por: Pan, Deng-hua, et al.
Publicado: (2017)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
por: Chai, Ruichao, et al.
Publicado: (2021)

In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma
por: Donskov, F, et al.
Publicado: (2004)

Prognostic and clinicopathological value of Ki-67/MIB-1 expression in renal cell carcinoma: a meta-analysis based on 4579 individuals
por: Wang, Zhun, et al.
Publicado: (2017)

Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2021)

Adult IDH Wild-Type Glioblastoma Ultrastructural Investigation Suggests a Possible Correlation between Morphological Biomarkers and Ki-67 Index
por: Familiari, Pietro, et al.
Publicado: (2023)

Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
por: Mareike, Müller, et al.
Publicado: (2021)

Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients
por: Priambada, Dody, et al.
Publicado: (2023)

Combined Epidermal Growth Factor Receptor and Beclin1 Autophagic Protein Expression Analysis Identifies Different Clinical Presentations, Responses to Chemo- and Radiotherapy, and Prognosis in Glioblastoma
por: Tini, Paolo, et al.
Publicado: (2015)

A Husband and a Wife with Simultaneous Presentation of Glioblastoma Multiforme: A Case Report
por: Roviello, Giandomenico, et al.
Publicado: (2013)

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
por: Combs, Stephanie E, et al.
Publicado: (2011)

Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma
por: Schiffgens, Salveena, et al.
Publicado: (2016)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
por: Incekara, Fatih, et al.
Publicado: (2020)

Arterial Spin Labeling Perfusion in Determining the IDH1 Status and Ki-67 Index in Brain Gliomas
por: Batalov, Artem I., et al.
Publicado: (2022)

Expression of Ki67 as detected by MIB-1 and its association with histopathological high-risk factors among patients with retinoblastoma tumour: a cross-sectional study
por: Vuhahula, Edda AM, et al.
Publicado: (2022)

Is Edema Zone Volume Associated With Ki-67 Index in Glioblastoma Patients?
por: Caramanti, Ricardo, et al.
Publicado: (2022)

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
por: Incekara, Fatih, et al.
Publicado: (2020)

ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors
por: Cai, Jinquan, et al.
Publicado: (2016)

Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas - an immunohistochemical study
por: Habberstad, Andreas H, et al.
Publicado: (2011)

Immune-Related lncRNA Risk Signatures Predict Survival of IDH Wild-Type and MGMT Promoter Unmethylated Glioblastoma
por: Li, Xiaozhi, et al.
Publicado: (2020)

MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy
por: Dumke, R., et al.
Publicado: (2022)

General Clinico-Pathological Characteristics in Glioblastomas in Correlation with p53 and Ki67
por: Sipos, Tamás-Csaba, et al.
Publicado: (2023)

IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma
por: Zeng, Ailiang, et al.
Publicado: (2015)

Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u24endjhk03kng01mjkijncs86